Business Context and Reporting Period
This Form 8-K is a current report filed by Conversion Labs, Inc. (not Lifemd, Inc.) on November 27, 2020. The filing addresses executive leadership changes and unregistered equity sales. The company is incorporated in Delaware and operates in the direct-to-consumer, FinTech, and healthcare sectors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and compensation arrangements rather than financial performance.
Material Changes
- Executive Departure: Stefan Galluppi resigned as Chief Operating Officer (COO) effective November 27, 2020. He will remain as Chief Technology Officer and a Board Member. The resignation was not due to any disagreement with the company.
- Executive Appointment: Brad Roberts was appointed as the new Chief Operating Officer on November 27, 2020.
- Unregistered Equity Sale: The company granted a stock option to Brad Roberts covering 200,000 shares of common stock. These securities were issued under Section 4(a)(2) and/or Regulation D exemptions and were not registered under the Securities Act of 1933.
Guidance, Outlook, and Compensation Details
Management commentary indicates that Mr. Roberts' experience in direct-to-consumer, FinTech, and healthcare industries qualifies him to lead the company toward continued growth. No specific financial guidance or outlook was provided in this filing.
Compensation and Agreements
- Employment Agreement: Mr. Roberts receives an annual base salary of $96,000. He is eligible for a performance bonus at the Board's discretion. Severance includes six months of base salary if terminated without cause.
- Consulting Agreement: The company entered a 36-month agreement with JDM Investments, LLC (owned by Mr. Roberts) to support call center operations. JDM receives a monthly fee of $17,000 plus a potential metric-based quarterly performance bonus.
Investor Verification Checklist
- Verify the distinction between the registrant name (Conversion Labs, Inc.) and the metadata label (Lifemd, Inc.).
- Review the full text of the Employment Agreement (Exhibit 10.1) and Consulting Agreement (Exhibit 10.2) for detailed terms not summarized in the 8-K.
- Confirm the impact of the new COO's consulting arrangement on related party transactions and future operating expenses.
- Check subsequent filings for the vesting schedule and exercise price of the 200,000 stock options granted to Mr. Roberts.